Verition Fund Management
RARE icon

Verition Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Verition Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-282,376
Closed -$6.49M – 3301
2025
Q4 		$6.49M Buy
282,376
+258,856
+1,101% +$8.51M 0.03% 701
2025
Q3 		$707K Sell
23,520
-27,986
-54% -$839K ﹤0.01% 2798
2025
Q2 		$1.87M Buy
51,506
+4,474
+10% +$161K 0.01% 2009
2025
Q1 		$1.7M Sell
47,032
-238,009
-83% -$9.9M 0.01% 1691
2024
Q4 		$12M Buy
285,041
+207,735
+269% +$10.3M 0.05% 445
2024
Q3 		$4.29M Sell
77,306
-60,125
-44% -$3.06M 0.02% 956
2024
Q2 		$5.65M Buy
137,431
+21,506
+19% +$918K 0.03% 657
2024
Q1 		$5.41M Buy
115,925
+108,855
+1,540% +$5.13M 0.04% 617
2023
Q4 		$338K Buy
+7,070
New +$274K ﹤0.01% 1737
2023
Q3 		– Sell
-7,507
Closed -$346K – 2621
2023
Q2 		$346K Buy
7,507
+1,166
+18% +$54.1K ﹤0.01% 1456
2023
Q1 		$254K Buy
6,341
+1,294
+26% +$55.5K ﹤0.01% 1625
2022
Q4 		$234K Sell
5,047
-6,316
-56% -$248K ﹤0.01% 1647
2022
Q3 		$471K Buy
+11,363
New +$584K 0.01% 1936
2022
Q2 		– Sell
-89,483
Closed -$6.5M – 2932
2022
Q1 		$6.5M Buy
+89,483
New +$6.23M 0.08% 277
2021
Q3 		– Sell
-38,948
Closed -$3.71M – 2238
2021
Q2 		$3.71M Buy
+38,948
New +$4.06M 0.03% 309
2020
Q1 		– Sell
-15,793
Closed -$675K – 975
2019
Q4 		$675K Buy
+15,793
New +$652K 0.01% 570
2019
Q2 		– Sell
-9,378
Closed -$650K – 1316
2019
Q1 		$650K Buy
+9,378
New +$536K 0.03% 559

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Verition Fund Management's RARE Position: Q1 2026 in Review

Verition Fund Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 282,376 shares — an estimated $6.49M sold.

Verition Fund Management first reported a position in RARE in Q1 2019 and held it in 17 quarters. The position peaked at $12M in Q4 2024. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Verition Fund Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 282,376 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $6.49M.
  • Verition Fund Management first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 17 quarters.
  • Verition Fund Management's Ultragenyx Pharmaceutical position peaked at $12M in Q4 2024.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.